Dr. Berry on LHRH Antagonists Versus Agonists for Prostate Cancer

William R. Berry, MD
Published: Tuesday, Oct 31, 2017



William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Before LHRH antagonists, there was a concern for patients who presented with metastatic disease, particularly metastatic disease in the bone, states Berry. Many of these patients would experience a surge of bone pain after starting therapy.

There is an indication to use the antagonist as they present with fewer symptoms than agonists, explains Berry.
 


William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Before LHRH antagonists, there was a concern for patients who presented with metastatic disease, particularly metastatic disease in the bone, states Berry. Many of these patients would experience a surge of bone pain after starting therapy.

There is an indication to use the antagonist as they present with fewer symptoms than agonists, explains Berry.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x